EN ESTA TEMPORADA FESTIVA, ST. JUDE CHILDREN’S RESEARCH HOSPITAL TE INVITA A PARTICIPAR EN SU CAMPAÑA THANKS AND GIVING. ® UN PROGRAMA ANUAL QUE BUSCA CREAR CONCIENCIA Y RECAUDAR FONDOS PARA COMBATIR EL CÁNCER INFANTIL.
Lancôme is unveiling Genes Day on October 22, a one day fundraiser in support of St. Jude Children’s Research Hospital.
In celebration of the beauty of scientific research, Lancôme will donate $7 from each bottle of their latest skin care breakthrough, Génifique Youth Activating Concentrate, sold that day to St. Jude Children’s Research Hospital to support the research and treatment at St. Jude.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/lancome/46646/
Sears and Kmart are spreading the holiday spirit early by changing the lives of one very special family and two well deserving charities as they announce the grand prize winner of the Shop Your Way Rewards “What Would You Do With One Billion Points?” contest. Todd Benjamin, resident of Lakewood, Colo., was named the winner for the national Sears and Kmart contest and received half of the prize value and the other half will be donated to the Rocky Mountain Rett Association (RMRA) and St. Jude Children’s Research Hospital.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/sears/47344/
On October 21st, 2011, Lancôme invites customers to experience the “Beauty of Giving” by celebrating Genes Day, a one-day national event Lancôme began in 2010 to support St. Jude Children’s Research Hospital, one of the world’s premier centers for the research and treatment of pediatric cancer and other catastrophic childhood diseases. On this day, Lancôme will donate $7 from the sale of every bottle of Génifique Youth Activating Concentrate to St. Jude. (This is in addition to special promotions and events nationwide surrounding Genes Day throughout the month of October.)
To view Multimedia News Release, go to http://www.multivu.com/mnr/52300-lancome-genes-day-2011-st-jude-julia-roberts-genifique-beauty-of-giving
Wolfram P. Kastner und Martin Krenn,
Schwere Sachbeschädigung – oder notwendige Ergänzung eines gefälschten Zitats?
Die Republik Österreich, Landesgericht Salzburg, hat gegen den Künstler Wolfram P. Kastner, der zusammen mit Martin Krenn eine Klasse an der Sommerakademie für Bildende Kunst 2001 leitete, ein Strafverfahren wegen „schwerer Sachbeschädigung“ eingeleitet und ein deutsches Amtsgericht um Amtshilfe und „Abhörung“ ersucht.
Was ist der Grund?
Der Begründer des Zionismus, Dr. Theodor Herzl, der sein Rechtsreferendariat am Salzburger Landesgericht ableistete, schrieb in sein Tagebuch: „In Salzburg brachte ich einige der glücklichsten Stunden meines Lebens zu. Ich wäre auch gerne in dieser schönen Stadt geblieben, aber als Jude wäre ich nie zur Stellung eines Richters befördert worden.“
Die Stadt Salzburg brachte im Jahr 2001 dort eine Marmortafel mit dem sinnentstellend verkürzten Zitat an: „In Salzburg brachte ich einige der glücklichsten Stunden meines Lebens zu.“
Am 29. August 2001 nahmen Wolfram P. Kastner und Martin Krenn mit den Studierenden in aller Öffentlichkeit eine handschriftliche Vervollständigung des Zitats vor. Sie sahen darin eine „Rückgabe der unterschlagenen Worte“, in der Hoffnung, daß dies die Verantwortlichen dazu bewegen könnte, ihren Fehler zu erkennen und zu verbessern.
Martin Krenn: „Die Tendenz zur Kriminalisierung von politischen Aktionen und die Einschränkung der künstlerischen Freiheit nimmt in Österreich bedauerlicher Weise zu. Aus meiner Sicht muß dem entschieden entgegen getreten werden.“
Researchers have identified the first gene mutation associated with a chronic and often fatal form of neuroblastoma that typically strikes adolescents and young adults. The finding provides the first clue about the genetic basis of the long-recognized but poorly understood link between treatment outcome and age at diagnosis.
The study involved 104 infants, children and young adults with advanced neuroblastoma, a cancer of the sympathetic nervous system. Investigators discovered the ATRX gene was mutated only in patients age 5 and older. The alterations occurred most often in patients age 12 and older. These older patients were also more likely than their younger counterparts to have a chronic form of neuroblastoma and die years after their disease is diagnosed.
To view Multimedia News Release, go to http://www.multivu.com/mnr/52992-st-jude-pediatric-cancer-genome-project-neuroblastoma-research
Researchers have discovered that a subtype of leukemia characterized by a poor prognosis is fueled by mutations in pathways distinctly different from a seemingly similar leukemia associated with a much better outcome. The findings from the St. Jude Children’s Research Hospital — Washington University Pediatric Cancer Genome Project (PCGP) highlight a possible new strategy for treating patients with this more aggressive cancer.
The work provides the first details of the genetic alterations fueling a subtype of acute lymphoblastic leukemia (ALL) known as early T-cell precursor ALL (ETP-ALL). The results suggest ETP-ALL has more in common with acute myeloid leukemia (AML) than with other subtypes of ALL. The study appears in the January 12 edition of the journal Nature.
To view Multimedia News Release, go to http://www.multivu.com/mnr/46768-st-jude-cancer-genome-sequencing-project-combat-aggressive-leukemia
Symptoms improved significantly in adults with the bleeding disorder hemophilia B following a single treatment with gene therapy developed by researchers at St. Jude Children’s Research Hospital in Memphis and demonstrated to be safe in a clinical trial conducted at the University College London (UCL) in the U.K.
The findings of the six-person study mark the first proof that gene therapy can reduce disabling, painful bleeding episodes in patients with the inherited blood disorder. Results of the Phase I study appear in the December 10 online edition of the New England Journal of Medicine. The research is also scheduled to be presented December 11 at the 53rd annual meeting of the American Society of Hematology in San Diego.
To view Multimedia News Release, go to http://www.multivu.com/mnr/46766-st-jude-children-s-research-hospital-gene-therapy-bleeding-disorder
New findings from the St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project (PCGP) have helped identify the mechanism that makes the childhood eye tumor retinoblastoma so aggressive. The discovery explains why the tumor develops so rapidly while other cancers can take years or even decades to form.
The finding also led investigators to a new treatment target and possible therapy for the rare childhood tumor of the retina, the light-sensing tissue at the back of the eye. The study appears in the January 11 advance online edition of the scientific journal Nature.
To view Multimedia News Release, go to http://www.multivu.com/mnr/46767-st-jude-genome-project-treatment-childhood-eye-tumor-retinoblastoma
To speed progress against cancer and other diseases, the St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project today announced the largest-ever release of comprehensive human cancer genome data for free access by the global scientific community. The amount of information released more than doubles the volume of high-coverage, whole genome data currently available from all human genome sources combined. This information is valuable not just to cancer researchers, but also to scientists studying almost any disease.
To view Multimedia News Release, go to http://www.multivu.com/mnr/52993-st-jude-childrens-research-hospital-comprehensive-human-cancer-genome-data
It was January 2012, Isaac dribbled the ball; shot it through the hoop, swish! This was a simple moment the 15-year-old athlete who once participated in cross country, soccer and basketball, thought he’d never experience again. Ten months earlier, Isaac was diagnosed with a brain tumor. He became a patient at St. Jude Children’s Research Hospital® and through extensive treatment and care, his cancer is in remission and he is able to play the sports he loves.
Chili’s® Grill & Bar is helping St. Jude patients like Isaac enjoy their own special, everyday moments through the brand’s ninth annual Create-A-Pepper to Fight Childhood Cancer campaign. Participating Chili’s restaurants nationwide and in Puerto Rico are joining in the fight against childhood cancer and other life-threatening diseases. September is National Childhood Cancer Awareness month and through Sept. 26, Chili’s guests can help the cause by donating at their local restaurants and online.
To view Multimedia News Release, go to http://www.multivu.com/mnr/57540-chili-s-create-a-pepper-for-st-jude
St. Jude Children’s Research Hospital is launching a new series of public service announcements (PSAs) to help raise awareness and deepen the understanding of the hospital’s lifesaving mission through real St. Jude heroes – its patients and families. St. Jude has not produced national PSAs since 2003 and timed this new multichannel campaign to coincide with the hospital’s 50th anniversary.
The PSAs share St. Jude moments through patients and families like 10-year-old Angiel. Angiel and her mom Damaris were planning a trip to Africa for a family reunion when she was diagnosed with osteosarcoma, a type of bone cancer that produced tumors in both of Angiel’s legs. Today, thanks to St. Jude doctors, Angiel can still look forward to visiting family in a foreign land one day. Angiel’s story is just one of several patients featured in the PSAs.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/stjude/46749/
